Gathering Data to Ascertain Biomarker Specificity in HER2– Breast Cancer

Although there is data for fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) as a treatment for HER2-positive, HER2-low, and HER2-ultra low breast cancer, data is still emerging among patients with HER2-negative disease, according to Adriana Kahn, MD.

Kahn, an assistant professor of Medical Oncology and Hematology in the Center for Breast Cancer and the Drug Development Department at Yale Cancer Center, discussed how her presentation of the phase 2 HER2 PARADIGM trial (NCT06750484) evaluating patients with previously treated HER2-immunohistochemistry (IHC) 0 advanced breast cancer ties into and builds upon prior research investigating T-DXd in patients with HER2-mutated disease. She presented these findings at the 2025 San Antonio Breast Cancer Symposium (SABCS).¹

She highlighted 3 studies that are investigating T-DXd in this HER2-negative population, one of which included a Yale-led initiative, and another was the European phase 2 DAISY trial (NCT04132960).² The latter, Kahn expressed, has results posted, but biomarker specificity has not been established based on the data.

Furthermore, she emphasized that ongoing studies are examining biomarkers that may inform the benefit of T-DXd, highlighting them as the key difference between trials examining the agent among patients with HER2-negative disease. Kahn concluded that subsequent data may help inform these benefits.

Transcript:

We have data on HER2-positive, HER2-low, and HER2-ultra low [disease]. We are adding data to the HER2-[negative] population. The [phase 2] DAISY study was a trial in Europe that treated patients in that setting, and they have released results, yet we do not know any specific biomarkers based on their data. We have our study with our Yale-born tests that we are doing, plus additional partners that joined…in the university and academic setting. And the company AstraZeneca is doing its own study now, which is a later event, after our study has been planned. [It] is a larger-scale study for the same [HER2-negative] population.

[Results are] coming from our study, prior studies, and future studies, but each of us is looking through different biomarkers. What makes a difference [between] all these studies is, individually, what can be done with those patients’ tissues and patients’ biomarkers to explore the potential biomarkers of selection and biomarkers [predicting] toxicity. We do not yet know how these are going to play with these patients. Gathering more data can help us understand that better.

References

1. Kahn A, Du J, Casasanta N, et al. Open-label single-arm phase 2 trial of trastuzumab deruxtecan in previously treated HER2-immunohistochemistry (IHC) 0 advanced breast cancer – HER2 PARADIGM trial. Presented at: 2025 San Antonio Breast Cancer Symposium; December 9-12, 2025; San Antonio, TX. Abstract PS5-08-07
2. Dieras VC, André F, Lusque A, et al. Trastuzumab deruxtecan (T-DXd) for advanced breast cancer (ABC) patients (pts), regardless of HER2 status: a phase II study with biomarkers analysis (DAISY) - update analysis with longer follow-up. ESMO Open. 2024;9(suppl 4):103016. doi:10.1016/j.esmoop.2024.103016